Welcome to our dedicated page for Forte Biosciences SEC filings (Ticker: FBRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Forte Biosciences, Inc. filings document a clinical-stage biopharmaceutical issuer focused on FB102, a proprietary anti-CD122 monoclonal antibody therapeutic candidate for autoimmune and autoimmune-related diseases. Its 8-K reports cover operating and financial results, Regulation FD clinical disclosures, material events, capital-structure matters and exhibits such as press releases and clinical presentations.
Proxy materials describe annual meeting matters, stockholder voting, board and compensation governance and equity incentive plan administration. The filing record also identifies Forte’s common stock, par value $0.001 per share, listed on Nasdaq under the symbol FBRX.
Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander report beneficial ownership of 655,199 shares of Forte Biosciences, Inc. common stock, representing 3.2% of the common stock class.
The reporting persons have no sole voting or dispositive power and instead report shared voting and shared dispositive power over all 655,199 shares. The securities are held by affiliated entities over which they exercise voting control or investment discretion, and they state this disclosure should not itself be construed as an admission of beneficial ownership. They also confirm ownership of 5 percent or less of the class.
Forte Biosciences reported positive Phase 1b results for FB102 in vitiligo from a double-blind, placebo-controlled study of 43 subjects. Patients were randomized 3:1, with 32 on FB102 and 11 on placebo.
The primary endpoint was facial vitiligo area severity index (FVASI) percent improvement at week 24. In the efficacy-evaluable population, FB102 achieved a 29.6% mean FVASI improvement from baseline versus 7.9% on placebo, for a placebo-adjusted benefit of 21.7 percentage points (p=0.020). Statistically significant separation from placebo emerged by day 64 and continued through week 24 after the 12‑week dosing period.
Subjects with more extensive baseline disease (FVASI ≥0.75) showed a 43.2% mean FVASI improvement at week 24 (p=0.006), with 58.8% reaching FVASI50 and 23.5% reaching FVASI75, compared with 0% on placebo. FB102’s safety profile remained favorable, with only mild to moderate treatment-emergent adverse events and no severe events reported.
Federated Hermes, Inc. amended a Schedule 13G/A to report ownership of 2,110,516 shares of Forte Biosciences common stock. The filing shows those shares represent 10.31% of the class as of 06/30/2026. The report includes a Rule 13d-4 disclaimer stating Federated Hermes, the Voting Shares Irrevocable Trust and named individuals expressly disclaim beneficial ownership of securities held by managed funds.
Forte Biosciences, Inc. chief financial officer Riley Antony reported compensation-related stock activity. On July 1, 2026, he exercised 375 Restricted Stock Units (RSUs), receiving the same number of Common Stock shares. To cover tax obligations, 134 Common Stock shares were disposed of via share withholding, not an open-market sale.
Following these transactions, Antony holds 42,600 Common Stock shares directly, according to the filing, which includes 377 shares acquired under the 2017 Employee Stock Purchase Plan. The activity reflects routine RSU vesting and tax withholding rather than discretionary buying or selling in the market.
Forte Biosciences director and officer Paul A. Wagner reported routine equity compensation activity. On July 1, 2026, he exercised restricted stock units to acquire 1,250 shares of Common Stock at a conversion price of $0.00 per share.
To cover tax obligations, 98 shares of Common Stock were disposed of in a tax-withholding transaction at $21.32 per share, which is not an open-market sale. After these transactions, Wagner directly owned 85,482 shares of Common Stock and 2,500 Restricted Stock Units, each RSU representing a contingent right to receive one share, subject to continued service and quarterly vesting under the 2021 Equity Incentive Plan.
Forte Biosciences, Inc. reported that Chief Financial Officer Antony A. Riley received a grant of stock options covering 22,000 shares of common stock. The options have an exercise price of $17.15 per share and expire on June 16, 2036.
According to the disclosure, all 22,000 option shares were held directly after the transaction, reflecting a compensation-related award rather than an open-market purchase. The footnotes state that, subject to continued service, one forty-eighth of the options will vest monthly starting on the Vesting Commencement Date of June 16, 2026, so the grant is scheduled to be fully vested four years after that date.
Forte Biosciences director and officer Paul A. Wagner received a grant of stock options for 500,000 shares of Common Stock. The options have an exercise price of $17.15 per share and expire on June 16, 2036. This is a compensation-related award, not an open-market purchase.
According to the vesting terms, beginning on the Vesting Commencement Date of June 16, 2026, one forty-eighth of the options vest each month, so the award becomes fully vested over four years if he continues as a service provider.
Forte Biosciences (Common Stock): A joint Schedule 13G filing states that Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander report shared voting and dispositive power over 1,062,182 shares, representing 5.2% of the class, with the cover date 06/04/2026. The filing explains these shares are held by entities subject to voting control and investment discretion by Millennium Management LLC and related managers. The filers executed a Joint Filing Agreement dated June 5, 2026 and provided the issuer address at 3060 Pegasus Park Drive, Building 6, Dallas, Texas 75247.
Forte Biosciences, Inc. amends its Form S-3 shelf registration to register up to $500,000,000 of securities to be offered from time to time, including common stock, preferred stock, debt securities, depositary shares, warrants, subscription rights, purchase contracts and units.
The prospectus updates incorporated documents and describes that specific terms and offering mechanics will be provided in prospectus supplements; proceeds treatment will be set forth in those supplements.